DOCSLIB.ORG

Gynecomastia: Its Features, and When and How to Treat It

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gynecomastia: Its Features, and When and How to Treat It REVIEW SHIRLEY A. BEMBO, MD HAROLD E. CARLSON, MD CME Division of Endocrinology, Diabetes, and Professor, Department of Medicine, and CREDIT Metabolism, State University of New York Head, Division of Endocrinology, Diabetes, at Stony Brook and Metabolism, State University of New York at Stony Brook Gynecomastia: Its features, and when and how to treat it ■ ABSTRACT YNECOMASTIA (enlargement of the male G breast) is usually benign. Yet, it causes Gynecomastia is common, being present in 30% to 50% much anxiety, psychosocial discomfort, and of healthy men. A general medical history and careful fear of breast cancer. physical examination with particular attention to features In this article we briefly review the causes suggestive of breast cancer often suffice for evaluation in of gynecomastia, the key features to look for in patients without symptoms or those with incidentally the history and the physical examination, who discovered breast enlargement. Men with recent-onset needs a more detailed evaluation, and when gynecomastia or mastodynia need a more detailed and how to treat this condition. evaluation, including selected laboratory tests to search ■ for an underlying cause. Treatment depends on the cause PREVALENCE AND OCCURRENCE and may include observation, withdrawal of an offending Gynecomastia is common. In two case series, drug, therapy of an underlying disease, giving androgen palpable breast tissue was detected on physical or antiestrogen drugs, or plastic surgery. examination in 36% of healthy younger adult men, 57% of healthy older men,1 and more ■ KEY POINTS than 70% of hospitalized elderly men.2 In autopsy studies, its prevalence was as high as Gynecomastia is probably not associated with an 55%.3 increased risk of breast cancer, except in Klinefelter Gynecomastia has three peaks of occur- syndrome. rence during the life span: The neonatal period. An estimated 60% Most cases of gynecomastia result from an imbalance to 90% of infants have transient gynecomastia between estrogenic (stimulatory) and androgenic due to transplacental transfer of maternal (inhibitory) effects on the breast. estrogens. It usually regresses completely by the end of the first year. Drug-induced gynecomastia accounts for 20% to 25% of Puberty. Gynecomastia may occur in 48% cases. Even with detailed evaluation, there is no to 64% of boys at puberty. It may first appear as identifiable cause in about 25% of cases. early as 10 years of age, with a peak onset between ages 13 and 14, followed by a decline in late teenage years. Late in life. The highest prevalence is among men ages 50 to 80.1,2 ■ HISTOLOGY Histologic studies reveal a proliferation of duc- This paper discusses therapies that are experimental or are not approved by the US Food and tules embedded in a connective tissue stroma; Drug Administration for the use under discussion. glandular acini are rare. In the early or florid CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 71 • NUMBER 6 JUNE 2004 511 Downloaded from www.ccjm.org on September 26, 2021. For personal use only. All other uses require permission. GYNECOMASTIA BEMBO AND CARLSON stage, ductal hyperplasia and proliferation are important. These may include excessive local extensive while the stroma is loose and ede- production of estrogen due to increased aro- matous. matase activity, decreased estrogen degrada- Usually, over about 12 months, the breast tion, or changes in androgen or estrogen tissue evolves into a quiescent stage, in which receptors.5 the amount of stroma and fibrosis increases Hyperprolactinemia is not believed to play and the ductules become less prominent. This a direct role in gynecomastia, although pro- distinction seems to be unimportant diagnos- lactin receptors have recently been demon- tically, as these microscopic findings are the strated in gynecomastia tissue.8 Most patients same regardless of the cause of the gynecomas- with gynecomastia have normal serum pro- tia.3,4 lactin levels.9 Moreover, not all patients with hyperprolactinemia have gynecomastia. ■ CLINICAL CHARACTERISTICS Elevated prolactin levels may, however, sup- press gonadotropin release, producing sec- Pseudogynecomastia (fatty breasts) is common ondary hypogonadism, which then contributes in obese men and needs to be differentiated to the development of gynecomastia. from true gynecomastia. In true gynecomastia, there may be a button of firm subareolar tissue, Absolute estrogen excess or there may be a more diffuse collection of Exogenous estrogens. The simplest fibroglandular tissue that resembles that of the mechanism underlying gynecomastia is female breast, and which may be difficult to absolute estrogen excess, as with the use of distinguish from simple adiposity. Comparing diethylstilbestrol in the treatment of advanced the subareolar tissue with the anterior axillary prostatic carcinoma.6 Cases have also resulted fold or other subcutaneous tissue may help in from unintended exposure to exogenous estro- differentiating true gynecomastia from gens in vaginal creams and hair lotions.10,11 pseudogynecomastia.5 Leydig cell tumors are rare testicular Although commonly bilateral and sym- tumors that secrete estradiol; about 90% are Gynecomastia metric, gynecomastia of any cause may be uni- benign. Most patients are young to middle- is present in lateral or asymmetric. Unilateral gynecomas- aged.12,13 The increased serum estradiol level tia seems to be more common on the left side.4 suppresses pituitary luteinizing hormone one third to Gynecomastia is often asymptomatic and (LH), leading to decreased serum testosterone. one half of may be an incidental finding on routine exam- Elevated serum estradiol also stimulates the ination, but breast pain or tenderness may be production of sex hormone-binding globulin healthy men present, particularly if the onset of the condi- (SHBG), which preferentially binds testos- tion is recent. terone, leading to decreased free testosterone Breast cancer accounts for only 0.2% of all with normal or elevated free estradiol. Leydig malignancies in men,5 and generally presents cell tumors are small and, in some cases, non- as a unilateral firm mass, often eccentric in palpable. If they are nonpalpable, testicular location rather than centered beneath the are- sonography or thermography may be needed ola. Skin dimpling, nipple retraction, nipple to detect them. Treatment remains surgical. discharge, and axillary lymphadenopathy may Estrogen-producing adrenal tumors, be seen. although rare, are usually malignant and are often quite large when discovered.14 In about ■ AN IMBALANCE OF ESTROGENS one half of cases, there is a palpable abdomi- OVER ANDROGENS nal mass. They tend to secrete large amounts of estrogen precursors such as androstene- Estrogens stimulate breast tissue growth, dione, dehydroepiandrosterone (DHEA), and whereas androgens inhibit it.6,7 Most cases of DHEA sulfate, and some directly produce gynecomastia appear to result from an imbal- estradiol and estrone.15 Two thirds of patients ance between estrogenic and androgenic have elevations of urinary 17-ketosteroids, effects on the breast. and some have elevated serum DHEA sulfate, Local tissue factors in the breast may be both of which are useful tumor markers. 512 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 71 • NUMBER 6 JUNE 2004 Downloaded from www.ccjm.org on September 26, 2021. For personal use only. All other uses require permission. Tumors producing chorionic gonado- chromosome plays a role in the development tropin. The placental hormone human chori- of breast cancer is uncertain, although some onic gonadotropin (hCG) is similar to LH in studies suggest it; a plausible mechanism is both its structure and its action on the testis. that expression of genes on the noninactivat- Thus, elevated serum levels of hCG dispro- ed portions of the second X chromosome facil- portionately stimulate normal Leydig cells of itates the development of the cancer. the testis to secrete increased amounts of Fibroblasts from patients with the XXY geno- estradiol. In addition, many hCG-secreting type have also been shown to have an tumors can take up estrogen precursors from increased rate of transformation after expo- the circulation and aromatize them into sure to simian virus 40. active estrogens. Secondary hypogonadism. Although less A variety of tumors can secrete hCG, common, gynecomastia may also be a conse- including testicular germ cell tumors and quence of androgen deficiency in secondary bronchogenic, liver, and gastric carcino- hypogonadism due to partial hypopituitarism. mas.13 Measurement of serum beta-hCG by In this situation, peripheral aromatization of immunoassay is used for diagnosis. Normal adrenal androgens to estrogens remains unaf- men have undetectable serum levels of hCG fected and maintains normal serum estrogen in commercially available assays. levels. Puberty. Gynecomastia develops in about Relative estrogen excess two thirds of boys during puberty. There are Aging seems to be associated with pro- periods during puberty when the balance of gressive testicular dysfunction, with low or sex hormone secretion favors estrogen,12 low-normal serum testosterone levels and, in despite an increase in androgen production. some cases, elevated LH.16 Total and free This ratio returns to more normal adult values serum estradiol concentrations remain nor- as puberty advances. The condition is usually mal. The exact mechanism of testicular failure asymptomatic and self-limited and regresses remains unknown. spontaneously after about 2 years.
Load more

Recommended publications
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Gynecomastia-Like Hyperplasia of Female Breast
    Case Report Annals of Infertility & Reproductive Endocrinology Published: 25 May, 2018 Gynecomastia-Like Hyperplasia of Female Breast Haitham A Torky1*, Anwar A El-Shenawy2 and Ahmed N Eesa3 1Department of Obstetrics-Gynecology, As-Salam International Hospital, Egypt 2Department of Surgical Oncology, As-Salam International Hospital, Egypt 3Department of Pathology, As-Salam International Hospital, Egypt Abstract Introduction: Gynecomastia is defined as abnormal enlargement in the male breast; however, histo-pathologic abnormalities may theoretically occur in female breasts. Case: A 37 years old woman para 2 presented with a right painless breast lump. Bilateral mammographic study revealed right upper quadrant breast mass BIRADS 4b. Wide local excision of the mass pathology revealed fibrocystic disease with focal gynecomastoid hyperplasia. Conclusion: Gynecomastia-like hyperplasia of female breast is a rare entity that resembles malignant lesions clinically and radiological and is only distinguished by careful pathological examination. Keywords: Breast mass; Surgery; Female gynecomastia Introduction Gynecomastia is defined as abnormal enlargement in the male breast; however, the histo- pathologic abnormalities may theoretically occur in female breasts [1]. Rosen [2] was the first to describe the term “gynecomastia-like hyperplasia” as an extremely rare proliferative lesion of the female breast which cannot be distinguished from florid gynecomastia. The aim of the current case is to report one of the rare breast lesions, which is gynecomastia-like hyperplasia in female breast. Case Presentation A 37 years old woman para 2 presented with a right painless breast lump, which was accidentally OPEN ACCESS discovered 3 months ago and of stationary course. There was no history of trauma, constitutional symptoms or nipple discharge.
    [Show full text]
  • Severe Gynaecomastia Associated with Spironolactone Treatment in A
    Journal of Pre-Clinical and Clinical Research, 2015, Vol 9, No 1, 92-95 www.jpccr.eu CASE REPORT Severe gynaecomastia associated with spironolactone treatment in a patient with decompensated alcoholic liver cirrhosis – Case report Katarzyna Schab1, Andrzej Prystupa2, Dominika Mulawka3, Paulina Mulawka3 1 1st Military Teaching Hospital and Polyclinic, Lublin, Poland 2 Department of Internal Medicine, Medical University, Lublin, Poland 3 Cardinal Stefan Wyszyński District Specialist Hospital, Lublin, Poland Schab K, Prystupa A, Mulawka D, Mulawka P. Severe gynaecomastia associated with spironolactone treatment in a patient with decompensated alcoholic liver cirrhosis – Case report. J Pre-Clin Clin Res. 2015; 9(1): 92–95. doi: 10.5604/18982395.1157586 Abstract Gynaecomastia is uni- or bilateral breast enlargement in males associated with benign hyperplasia of the glandular, fibrous and adipose tissue resulting from oestrogen-androgen imbalance. Asymptomatic gynaecomastia is a common finding in healthy male adults and does not have to be treated, while symptomatic gynaecomastia might be the symptoma of many pathological conditions and requires meticulous diagnosis and therapeutic management. The commonest causes of gynaecomastia in the Polish population include liver cirrhosis and drugs used to treat its complications. The current study presents the case of severe painless gynaecomastia in a patient with decompensated alcoholic liver cirrhosis, treated with spironolactone because of ascites. Breast enlargement assessed a IIb according to the Simon’s Scale or III according to the Cordova-Moschella classification, developed slowly over the two-year period of low-dose spironolactone therapy The course and dynamics of disease are described and the main mechanisms leading to its development discussed.
    [Show full text]
  • Gynecomastia — a Difficult Diagnostic Problem Ginekomastia — Trudny Problem Diagnostyczny
    SZKOLENIE PODYPLOMOWE/POSTGRADUATE EDUCATION Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 2/2011 ISSN 0423–104X Gynecomastia — a difficult diagnostic problem Ginekomastia — trudny problem diagnostyczny Marek Derkacz1, Iwona Chmiel-Perzyńska2, Andrzej Nowakowski1 1Department of Endocrinology, Medical University, Lublin, Poland 2Department of Family Medicine, Medical University, Lublin, Poland Abstract Gynecomastia is a benign, abnormal, growth of the male breast gland which can occur unilaterally or bilaterally, resulting from a prolife- ration of glandular, fibrous and adipose tissue. Gynecomastia is characterised by the presence of soft, 2–4 cm in diameter, usually discus- shaped enlargement of tissues under the nipple. It is estimated that this pathology occurs in 32–65% of men over the age of 17. Gynecoma- stia is a psychosocial problem and may lead to a perceived lowering of quality of life. The main cause of gynecomastia is a loss of equilibrium between oestrogens and androgens. Increased sensitivity for oestrogens of the breast gland, or local factors (e.g. an excessive synthesis of oestrogens in breast tissues or changes in oestrogen and androgen receptors) may cause gynecomastia. Also, prolactin, thyroxine, cortisol, human chorionic gonadotropin, leptin and receptors for human chorionic gonadotropin, prolactin and luteinizing hormone localised in tissues of the male breast may participate in the etiopathogenesis of gyneco- mastia. Usually three types of gynecomastia are distinguished: physiological, idiopathic and pathological gynecomastia. The latter is the consequ- ence of relative or absolute excess of oestrogens. In this paper, frequent as well as casuistic causes of gynecomastia will be described. A diagnosis of gynecomastia is usually possible after a palpation examination.
    [Show full text]
  • Evaluation of the Symptomatic Male Breast
    Revised 2018 American College of Radiology ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast Variant 1: Male patient of any age with symptoms of gynecomastia and physical examination consistent with gynecomastia or pseudogynecomastia. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Not Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Not Appropriate ☢☢ US breast Usually Not Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 2: Male younger than 25 years of age with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O Mammography diagnostic May Be Appropriate ☢☢ Digital breast tomosynthesis diagnostic May Be Appropriate ☢☢ MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 3: Male 25 years of age or older with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Appropriate ☢☢ US breast May Be Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 4: Male 25 years of age or older with indeterminate palpable breast mass. Mammography or digital breast tomosynthesis indeterminate or suspicious. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O ACR Appropriateness Criteria® 1 Evaluation of the Symptomatic Male Breast Variant 5: Male of any age with physical examination suspicious for breast cancer (suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction).
    [Show full text]
  • Findings of Gynecomastia That Developed in Follow-Up Secondary
    Interesting Image Mol Imaging Radionucl Ther 2020;29:82-84 DOI:10.4274/mirt.galenos.2019.50490 Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan Kemik Sintigrafisinde Bicalutamide Tedavisine Sekonder Takipte Gelişen Jinekomasti Bulguları Kemal Ünal1, Nahide Gökçora2 1Acıbadem University, Department of Nuclear Medicine, İstanbul, Turkey 2Gazi University, Department of Nuclear Medicine, Ankara, Turkey Abstract Prostate cancer is a common neoplastic disease especially in elder patients. Metastatic prostate disease has low five-year survival rate. Bicalutamide is an androgen receptor antagonist that acts as an inhibitor by competizing androgen receptors in the target tissue and used as a treatment option in prostate cancer. Bone scan was performed on a 79-year-old male with prostate cancer in our department. Blood pool images showed bilateral hyperemia in the breast regions which was not present on the previous scan one year ago. On physical examination, there was bilateral painful gynecomastia. It was learned that the patient was given Bicalutamide therapy after the first bone scan. Blood pool images may detect this side effect and should be evaluated with physical examination in case of clinical doubt. Keywords: Bicalutamide, gynecomastia, bone scan, prostate cancer Öz Prostat kanseri, ileri yaşlarda görülme sıklığı artan ve uzak metastazı olan hastalarda 5 yıllık sağkalım oranı önemli ölçüde düşük seyreden bir neoplazidir. Bicalutamide, prostat kanserli hastalarda kullanılan ve hedef dokudaki androjen reseptörleri ile kompetisyona girerek inhibitör etki gösteren bir ilaçtır. Prostat kanseri nedeniyle takip edilen 79 yaşındaki erkek hastaya bölümümüzde kemik sintigrafisi çekildi. Kan havuzu görüntülerinde bir yıl önceki incelemesinde gözlenmeyen, her iki meme bölgesinde hiperemi gelişimi görüldü.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use PRASTERA® Safely and Effectively
    PRASTERA- prasterone and ibuprofen Health Science Funding, LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRASTERA® safely and effectively. See full prescribing information for PRASTERA® . PRASTERA® prasterone oral softgels 200mg are for oral use only. Initial U.S. Approval INDICATIONS AND USAGE PRASTERA® prasterone 200 mg oral softgels is indicated in female patients with mild to moderate, active (SLEDAI ≥2) systemic lupus erythematosus (SLE) to restore serum 5-dehydroandrosterone sulfate to levels typical of women without SLE. In Phase III clinical trials in female patients with mild to moderate active SLE, prasterone 200 mg was associated with reduced risk of auto-immune flare, reduced risk of breast cancer and reduced risk of death from any cause. (§§1, 6.2, 6.4, 6.5) DOSAGE AND ADMINISTRATION The recommended dose is one (1) softgel daily. (§2) DOSAGE FORMS AND STRENGTHS 200mg oral softgel capsules supplied in a convenience package with ibuprofen oral tablets 400mg. (§3) CONTRAINDICATIONS Known hypersensitivity to any of its ingredients. (§4) Undiagnosed abnormal genital bleeding. (§4) Known, suspected or history of breast cancer. (§4, §6.5) History of, or known, deep vein thrombosis, pulmonary embolism, arterial thromboembolic disease (e.g., stroke, myocardial infarction). (§4) Hypercholesterolemia or ischemic heart disease. (§4, §7.2.4) Hepatic or renal impairment (pharmacokinetic data lacking). (§4, §7.2) Breast-feeding or known or suspected pregnancy.
    [Show full text]
  • A Guide to Medications for the LGBT2SQ Population
    Smashing Stigma: A guide to medications for the LGBT2SQ population HORMONE THERAPY FOR GENDER TRANSITION Some transgender individuals undergo gender-affirming hormone treatment to address the incongruity between their assigned sex at birth and their sense of gender. Individuals assigned male at birth who transition to female may take estrogen and anti-androgen therapies. Individuals assigned female at birth who transition to male may take testosterone therapy. Not all transgender patients take hormone replacement therapy (HRT), and not all patients on HRT identify within the gender binary — non-binary trans individuals may also want to transition medically. Provided to you by: © October 2019 FEMINIZING HORMONES Feminizing hormones are hormone regimens used by trans women and other individuals with the goal of developing typically-female secondary sex characteristics and suppression or minimization of typically-male secondary sex characteristics. Effects will include breast development, redistribution of body and facial subcutaneous fat, reduction of muscle mass and body hair, skin changes, reduction in erectile function, changes in libido and emotional and social functioning, and reduction of testicular size.i The expected onset of most of these changes will occur over 3-12 months of hormone therapy with maximal effects occurring over 2-5 years.i Anti-androgens Anti-androgens may be used to suppress the effect of endogenous androgens and thereby reduce masculine characteristics. The required estrogen dose to produce a feminising effect is reduced by the addition of an anti-androgen in the drug therapy regimen. SPIRONOLACTONE is a potassium-sparing CYPROTERONE is a synthetic progestogen diuretic that directly inhibits testosterone that demonstrates a strong anti-androgenic production and blocks androgen receptors at effect, typically resulting higher doses.
    [Show full text]
  • Prepubertal Gynecomastia: Indirect Exposure to Estrogen Cream
    Prepubertal Gynecomastia: Indirect Exposure to Estrogen Cream Eric I. Felner, MD, and Perrin C. White, MD ABSTRACT. Objective. To describe the clinical On physical examination, he was a large, active, and healthy course of 3 prepubertal boys who presented with gyneco- boy. His height, weight, and bone age were advanced (Table 1). mastia resulting from indirect exposure to a custom- Records from his general pediatrician revealed that his height was compounded preparation of estrogen cream used by each at the 75th percentile 6 months before his visit. Examination of his child’s mother. chest revealed Tanner II breast development with 2 cm of glan- dular breast tissue bilaterally. There was no areolar pigmentation. Methodology. Each child was initially referred to the The nipples were everted but without erythema, discharge, or Children’s Medical Center of Dallas’ Endocrinology Cen- tenderness. He had no pubic or axillary hair, body odor, acne, or ter and followed for over 1 year. penile enlargement. His testes were prepubertal and without Results. All 3 boys presented with gynecomastia and masses. He had no thyromegaly or hepatosplenomegaly, and the elevated estradiol levels. Two had accelerated growth remainder of his examination was normal. The family agreed to and advanced bone ages. Within 4 months after each have hormone studies collected at an outside facility, but despite child’s mother discontinued use of the topical estrogen attempts to contact and remind the family, they failed to follow-up preparation, each child’s gynecomastia regressed and es- with the laboratory. tradiol levels returned to normal. The patient returned to the Endocrine Center 6 months later Conclusion.
    [Show full text]
  • Download Article As
    NPWOMENSHEALTHCARE.COM September 2018 • Volume 6 • Number 3 Healthcare Womens The official journal of A clinical journal for NPs’ CONTINUING EDUCATION Managing women’s health issues across a lifespan Challenges of preconception Developing and implementing NPWH POSITION STATEMENT and interconception care: PrEP at your local health center Men with breast conditions: Environmental toxic exposures The role of the WHNP specializing in breast care A Publication STAFF Group Publisher Gregory P. Osborne Director, Marketing & Program Mgmt. Tyra London NPWH CEO EDITOR-IN-CHIEF Gay Johnson Beth Kelsey, EdD, APRN, WHNP-BC, FAANP Assistant Professor Editor-in-Chief School of Nursing Beth Kelsey, EdD, APRN, WHNP-BC, FAANP Ball State University Managing Editor Muncie, Indiana Dory Greene Art Director Michael F. Higgins EDITORIAL ADVISORY BOARD Lorraine Byrnes, PhD, FNP-BC, PMHNP-BC, CNM, FAANP Production Director Associate Professor/Associate Dean Undergraduate Nursing Programs Christian Evans Gartley Hunter College of the City University of New York New York, New York PUBLISHED BY Helen A. Carcio, MS, MEd, ANP-BC HealthCom Media Director, Health & Continence Institute of New England 259 Veterans Lane, Doylestown, PA 18901 South Deerfield, Massachusetts Telephone: 215/489-7000 Facsimile: 215/230-6931 Melanie Deal, MSN, WHNP-BC, FNP-BC Clinical Practice, University Health Services Chief Executive Officer University of California, Berkeley Gregory P. Osborne Barb Dehn, RN, MS, NP, FAANP, NCMP Executive Vice President, Sales & Operations Women’s Health
    [Show full text]
  • Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: a Case Report
    ANTICANCER RESEARCH 36: 3433-3436 (2016) Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report PEETER KARIHTALA1, TARJA RISSANEN2 and HANNU TUOMINEN3 1Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; Departments of 2Radiology and 3Pathology, Oulu University Hospital, Oulu, Finland Abstract. Phyllodes tumor in male breast is an exceptionally gynecomastia and mastalgia rates and it is, therefore, routinely rare neoplasm with only few published case reports. Herein, administrated in the beginning of bicalutamide treatment (7, 8). we present a case of malignant phyllodes tumor in male breast There are very few reports describing breast phyllodes nine years after prophylactic breast 10 Gy radiotherapy and tumor in men with few cases reported in the English after nine year bicalutamide treatment. The imaging findings literature. Usually, these tumors are associated with of the tumor and pathological correlation are also presented. gynecomastia, with various etiological factors reported (9- 18). To the best of our knowledge, the present study reports Phyllodes tumors are rare neoplasms with an incidence in the first case of male malignant phyllodes tumor occurring women that has been estimated to be <1% of all breast after bicalutamide treatment or radiotherapy. primary tumors. Phyllodes tumors contain both epithelial and stromal components and are classified as benign, borderline Case Report and malignant subtypes, although this classification does not necessarily optimally reflect tumor’s clinical behavior (1, 2). A sixty-eight-year-old man was diagnosed with cT3NxM0, Clinically, phyllodes tumors are usually rapidly growing and Gleason score 8 (4+4) prostate adenocarcinoma in December painless masses.
    [Show full text]
  • Aldactone® Spironolactone Tablets, USP
    NDA 12-151/S-062 Page 2 Aldactone® spironolactone tablets, USP WARNING Aldactone has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions). Aldactone should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. DESCRIPTION Aldactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula: Spironolactone is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, flavor, hypromellose, iron oxide, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide. ACTIONS / CLINICAL PHARMACOLOGY Mechanism of action: Aldactone (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Aldactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Aldactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone antagonist activity: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and the nephrotic syndrome. By competing with aldosterone for receptor sites, Aldactone provides effective therapy for the edema and ascites in those conditions.
    [Show full text]